<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35179228</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>65</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Muscle &amp; nerve</Title>
          <ISOAbbreviation>Muscle Nerve</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer-assisted evaluation.</ArticleTitle>
        <Pagination>
          <StartPage>560</StartPage>
          <EndPage>567</EndPage>
          <MedlinePgn>560-567</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27520</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION/AIMS">Myotonic dystrophy type 1 (DM1) is known to affect cognitive function, but the best methods to assess central nervous system involvement in multicenter studies have not been determined. In this study our primary aim was to evaluate the potential of computerized cognitive tests to assess cognition in DM1.</AbstractText>
          <AbstractText Label="METHODS">We conducted a prospective, longitudinal, observational study of 113 adults with DM1 at six sites. Psychomotor speed, attention, working memory, and executive functioning were assessed at baseline, 3 months, and 12 months using computerized cognitive tests. Results were compared with assessments of muscle function and patient reported outcomes (PROs), including the Myotonic Dystrophy Health Index (MDHI) and the 5-dimension EuroQol (EQ-5D-5L) questionnaire.</AbstractText>
          <AbstractText Label="RESULTS">Based on intraclass correlation coefficients, computerized cognitive tests had moderate to good reliability for psychomotor speed (0.76), attention (0.82), working memory speed (0.79), working memory accuracy (0.65), and executive functioning (0.87). Performance at baseline was lowest for working memory accuracy (P &lt; .0001). Executive function performance improved from baseline to 3 months (P &lt; .0001), without further changes over 1 year. There was a moderate correlation between poorer executive function and larger CTG repeat size (r = -0.433). There were some weak associations between PROs and cognitive performance.</AbstractText>
          <AbstractText Label="DISCUSSION">Computerized tests of cognition are feasible in multicenter studies of DM1. Poor performance was exhibited in working memory, which may be a useful variable in clinical trials. Learning effects may have contributed to the improvement in executive functioning. The relationship between PROs and cognitive impairment in DM1 requires further study.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Deutsch</LastName>
            <ForeName>Gayle K</ForeName>
            <Initials>GK</Initials>
            <Identifier Source="ORCID">0000-0001-6886-4356</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hagerman</LastName>
            <ForeName>Katharine A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampson</LastName>
            <ForeName>Jacinda</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dent</LastName>
            <ForeName>Gersham</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Biogen, Cambridge, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dekdebrun</LastName>
            <ForeName>Jeanne</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The University of Rochester Medical Center, Rochester, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parker</LastName>
            <ForeName>Dana M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thornton</LastName>
            <ForeName>Charles A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The University of Rochester Medical Center, Rochester, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heatwole</LastName>
            <ForeName>Chad R</ForeName>
            <Initials>CR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The University of Rochester Medical Center, Rochester, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Subramony</LastName>
            <ForeName>Sub H</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Norman Fixel Center for Neurological Disorders, University of Florida College of Medicine, Gainesville, FL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mankodi</LastName>
            <ForeName>Ami K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>National Institute of Neurological Disorders and Stroke, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ashizawa</LastName>
            <ForeName>Tetsuo</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Weill Cornell Medicine at Houston Methodist Hospital, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Statland</LastName>
            <ForeName>Jeffrey M</ForeName>
            <Initials>JM</Initials>
            <Identifier Source="ORCID">0000-0003-0790-5315</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, KS.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnold</LastName>
            <ForeName>W David</ForeName>
            <Initials>WD</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Neurology, PM&amp;R, Neuroscience and Physiology and Cell Biology, The Ohio State University, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moxley</LastName>
            <ForeName>Richard T</ForeName>
            <Initials>RT</Initials>
            <Suffix>3rd</Suffix>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The University of Rochester Medical Center, Rochester, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Day</LastName>
            <ForeName>John W</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Myotonic Dystrophy Clinical Research Network</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50 NS048843</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50NS048843</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Muscle Nerve</MedlineTA>
        <NlmUniqueID>7803146</NlmUniqueID>
        <ISSNLinking>0148-639X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003201" MajorTopicYN="N">Computers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009223" MajorTopicYN="Y">Myotonic Dystrophy</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">muscle disease</Keyword>
        <Keyword MajorTopicYN="Y">myotonic dystrophy type 1</Keyword>
        <Keyword MajorTopicYN="Y">neuropsychology</Keyword>
        <Keyword MajorTopicYN="Y">patient-reported outcome</Keyword>
        <Keyword MajorTopicYN="Y">quality of life</Keyword>
      </KeywordList>
      <CoiStatement>Disclosure of Conflicts of Interest: G.K. Deutsch: Served as a consultant to Biogen. J. Sampson: Served as a consultant for Dyne Therapeutics, Expansion Therapeutics and Viking Therapeutics. The remaining authors have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35179228</ArticleId>
        <ArticleId IdType="mid">NIHMS1781721</ArticleId>
        <ArticleId IdType="pmc">PMC9102286</ArticleId>
        <ArticleId IdType="doi">10.1002/mus.27520</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bird TD. Myotonic Dystrophy Type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle Copyright © 1993–2020, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.</Citation>
        </Reference>
        <Reference>
          <Citation>Winblad S, Samuelsson L, Lindberg C, Meola G. Cognition in myotonic dystrophy type 1: a 5-year follow-up study. Eur J Neurol
2016;23(9):1471–1476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27323306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallais B, Gagnon C, Mathieu J, Richer L. Cognitive decline over time in adults with myotonic dystrophy type 1: A 9-year longitudinal study. Neuromuscul Disord
2017;27(1):61–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27919548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modoni A, Silvestri G, Vita MG, Quaranta D, Tonali PA, Marra C. Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study. J Neurol
2008;255(11):1737–1742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18821050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gliem C, Minnerop M, Roeske S, Gartner H, Schoene-Bake JC, Adler S, Witt JA, Hoffstaedter F, Schneider-Gold C, Betz RC, Helmstaedter C, Tittgemeyer M, Amunts K, Klockgether T, Weber B, Kornblum C. Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study. PLoS One
2019;14(3):e0213381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6405094</ArticleId>
            <ArticleId IdType="pubmed">30845252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labayru G, Aliri J, Zulaica M, Lopez de Munain A, Sistiaga A. Age-related cognitive decline in myotonic dystrophy type 1: An 11-year longitudinal follow-up study. J Neuropsychol
2020;14(1):121–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7078919</ArticleId>
            <ArticleId IdType="pubmed">31407859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peric S, Rakocevic Stojanovic V, Mandic Stojmenovic G, Ilic V, Kovacevic M, Parojcic A, Pesovic J, Mijajlovic M, Savic-Pavicevic D, Meola G. Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. Neurol Sci
2017;38(3):415–423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27896491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve
2007;36(3):294–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17486579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashizawa T, Gagnon C, Groh WJ, Gutmann L, Johnson NE, Meola G, Moxley R 3rd, Pandya S, Rogers MT, Simpson E, Angeard N, Bassez G, Berggren KN, Bhakta D, Bozzali M, Broderick A, Byrne JLB, Campbell C, Cup E, Day JW, De Mattia E, Duboc D, Duong T, Eichinger K, Ekstrom AB, van Engelen B, Esparis B, Eymard B, Ferschl M, Gadalla SM, Gallais B, Goodglick T, Heatwole C, Hilbert J, Holland V, Kierkegaard M, Koopman WJ, Lane K, Maas D, Mankodi A, Mathews KD, Monckton DG, Moser D, Nazarian S, Nguyen L, Nopoulos P, Petty R, Phetteplace J, Puymirat J, Raman S, Richer L, Roma E, Sampson J, Sansone V, Schoser B, Sterling L, Statland J, Subramony SH, Tian C, Trujillo C, Tomaselli G, Turner C, Venance S, Verma A, White M, Winblad S. Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract
2018;8(6):507–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6294540</ArticleId>
            <ArticleId IdType="pubmed">30588381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collie A, Maruff P, Snyder PJ, Darekar MA, Huggins JP. Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. Hum Psychopharmacol
2006;21(7):481–488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16952205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collie A, Darekar A, Weissgerber G, Toh MK, Snyder PJ, Maruff P, Huggins JP. Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study. Contemp Clin Trials
2007;28(4):391–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17267292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol
2009;24(2):165–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19395350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mielke MM, Machulda MM, Hagen CE, Edwards KK, Roberts RO, Pankratz VS, Knopman DS, Jack CR Jr., Petersen RC. Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. Alzheimers Dement
2015;11(11):1367–1376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4595161</ArticleId>
            <ArticleId IdType="pubmed">25858683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cogstate Normative Data. www.cogstate.com
2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Heaton RK, Grant I
Matthews CG
Comprehensive norms for an expanded Halstead-Reitan Battery: Demographic corrections, research findings, and clinical applications. Odessa, FL: Psychological Assessment Resources; 1991.</Citation>
        </Reference>
        <Reference>
          <Citation>Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, Hilbert JE, Luebbe E, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley R, 3rd. Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure. Muscle Nerve
2014;49(6):906–914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5551891</ArticleId>
            <ArticleId IdType="pubmed">24142420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R, 3rd. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology
2012;79(4):348–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3400095</ArticleId>
            <ArticleId IdType="pubmed">22786587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, McDermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd. Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve
2016;53(2):183–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4979973</ArticleId>
            <ArticleId IdType="pubmed">26044513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heatwole C, Johnson N, Dekdebrun J, Dilek N, Eichinger K, Hilbert J, Luebbe E, Martens W, McDermott MP, Thornton C, Moxley R. Myotonic dystrophy patient preferences in patient-reported outcome measures. Muscle Nerve
2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res
2011;20(10):1727–1736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3220807</ArticleId>
            <ArticleId IdType="pubmed">21479777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology
2001;56(3):336–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11171898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT 3rd, Thornton CA. Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol
2013;74(6):862–872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4099006</ArticleId>
            <ArticleId IdType="pubmed">23929620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform
2009;42(2):377–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2700030</ArticleId>
            <ArticleId IdType="pubmed">18929686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Reporting; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>IBM Corp. Released 2019. IBM SPSS Statistics for Mac, Version 26.0. Armonk, NY: IBM Corp; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med
2016;15(2):155–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4913118</ArticleId>
            <ArticleId IdType="pubmed">27330520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate Use and Interpretation. Anesth Analg
2018;126(5):1763–1768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29481436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol
2004;61(12):1943–1947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15596617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winblad S, Lindberg C, Hansen S. Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1). Behav Brain Funct
2006;2:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1475858</ArticleId>
            <ArticleId IdType="pubmed">16696870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagnon C, Meola G, Hebert LJ, Puymirat J, Laberge L, Leone M. Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011. Neuromuscul Disord
2013;23(12):1056–1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24011704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okkersen K, Buskes M, Groenewoud J, Kessels RPC, Knoop H, van Engelen B, Raaphorst J. The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis. Cortex
2017;95:143–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28892766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The unity and diversity of executive functions and their contributions to complex “Frontal Lobe” tasks: a latent variable analysis. Cogn Psychol
2000;41(1):49–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10945922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wozniak JR, Mueller BA, Lim KO, Hemmy LS, Day JW. Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1. J Neurol Sci
2014;341(1–2):73–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4042407</ArticleId>
            <ArticleId IdType="pubmed">24768314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagnon C, Petitclerc E, Kierkegaard M, Mathieu J, Duchesne E, Hebert LJ. A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1. J Neurol
2018;265(7):1698–1705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29785524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuikka RA, Laaksonen RK, Somer HV. Cognitive function in myotonic dystrophy: a follow-up study. Eur Neurol
1993;33(6):436–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8307065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fredrickson J, Maruff P, Woodward M, Moore L, Fredrickson A, Sach J, Darby D. Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology
2010;34(2):65–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20016215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stoffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush A, Masters CL, Rowe CC, Ames D, Darby D, Maruff P. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). Arch Clin Neuropsychol
2013;28(4):320–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23552802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pietrzak RH, Maruff P, Mayes LC, Roman SA, Sosa JA, Snyder PJ. An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring. Arch Clin Neuropsychol
2008;23(4):433–445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18448309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, Cosottini M, Massimetti G, Tognoni G, Ricci G, Angelini C, Siciliano G. Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study. Orphanet J Rare Dis
2016;11:34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4820880</ArticleId>
            <ArticleId IdType="pubmed">27044540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton MJ, McLean J, Cumming S, Ballantyne B, McGhie J, Jampana R, Longman C, Evans JJ, Monckton DG, Farrugia ME. Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight. Front Neurol
2018;9:780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6176265</ArticleId>
            <ArticleId IdType="pubmed">30333784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yum K, Wang ET, Kalsotra A. Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes. Curr Opin Genet Dev
2017;44:30–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5447468</ArticleId>
            <ArticleId IdType="pubmed">28213156</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
